Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges.
暂无分享,去创建一个
J. Cleland | I. Gemmell | A C Rankin | A. Khand | A. Rankin | J G Cleland | I Gemmell | A U Khand
[1] Therapy Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure , 1993, The Lancet.
[2] G. Lamas,et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. , 1994, Circulation.
[3] S G Thompson,et al. Incidence and aetiology of heart failure; a population-based study. , 1999, European heart journal.
[4] J. Cleland,et al. Sudden death in heart failure: vascular or electrical? , 1999, European journal of heart failure.
[5] K. Swedberg,et al. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.
[6] J. Cleland,et al. Systematic review of the management of atrial fibrillation in patients with heart failure. , 2000, European heart journal.
[7] Y Wang,et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. , 1997, Archives of internal medicine.
[8] Annual Report of the Registrar-General , 1857, Journal of public health, and sanitary review.
[9] R. Cooper,et al. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. , 1988, Archives of internal medicine.
[10] L. Tavazzi,et al. Concomitant factors of decompensation in chronic heart failure. , 1996, The American journal of cardiology.
[11] CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.
[12] J. McMurray,et al. Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979-1992. , 1998, European heart journal.
[13] R. Falk,et al. The WASH study (warfarin/aspirin study in heart failure) rationale, design and end-points , 1999 .
[14] A. Michalsen,et al. Preventable causative factors leading to hospital admission with decompensated heart failure , 1998, Heart.
[15] B. Pitt,et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions , 1992, The Lancet.
[16] M. Rich,et al. Early Readmission of Elderly Patients With Congestive Heart Failure , 1990, Journal of the American Geriatrics Society.
[17] Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group. , 1995, Journal of clinical epidemiology.
[18] R. Patten,et al. Ventricular remodeling and its prevention in the treatment of heart failure. , 1998, Current opinion in cardiology.
[19] T. Inoue,et al. Heart failure progression due to secondary organ dysfunction in acute heart failure. , 1995, Japanese heart journal.
[20] L. Rydén,et al. Improved knowledge of antidiabetic treatment--a necessity for the modern cardiologist. , 1999, European heart journal.
[21] P C Deedwania,et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. , 1998, Circulation.
[22] Great Britain. Foreign Office.,et al. Forty-Fifth Annual Report of the Registrar-General for Scotland , 1900 .
[23] G. Murray,et al. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .
[24] D E Grobbee,et al. The epidemiology of heart failure. , 1997, European heart journal.
[25] M. Pfeffer,et al. Effect of left ventricular sphericity on the evolution of ventricular dysfunction in rats with diffuse isoproterenol-induced myocardial necrosis. , 1998, Journal of cardiac failure.
[26] J. McMurray,et al. Trends in hospitalization for heart failure in Scotland 1980-1990. , 1993, European heart journal.
[27] How accurate are SMR1 (Scottish Morbidity Record 1) data? , 1992, Health bulletin.
[28] G. Bonsel,et al. UvA-DARE ( Digital Academic Repository ) Cardiovascular disease in the Netherlands , 1975 to 1995 : decline in mortality , but increasing numbers of patients with chronic conditions , 1999 .
[29] A. Patel,et al. Scottish hospital morbidity data. 1. Errors in diagnostic returns. , 1976, Health bulletin.
[30] Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. , 1995, Circulation.
[31] L. Køber,et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. , 1999, Circulation.
[32] S. Kendrick,et al. The Scottish Record Linkage System. , 1993, Health bulletin.
[33] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[34] Knill-Jones Rp,et al. How accurate are SMR1 (Scottish Morbidity Record 1) data , 1992 .
[35] A. Jette,et al. Hospital Readmissions Among the Elderly , 1985, Journal of the American Geriatrics Society.
[36] A. Hoes,et al. Prevention of relapse in patients with congestive heart failure: the role of precipitating factors , 1998, Heart.
[37] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[38] S. Yusuf,et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. , 1994, Circulation.
[39] K Harley,et al. Quality of Scottish Morbidity Record (SMR) data. , 1996, Health bulletin.
[40] F. Tristani,et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.
[41] P. Lechat. Prevention of heart failure progression: current approaches. , 1998, European heart journal.
[42] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.
[43] J. Croft,et al. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. , 1999, American heart journal.
[44] D. Levy,et al. The epidemiology of heart failure: the Framingham Study. , 1993, Journal of the American College of Cardiology.
[45] G. Lamas,et al. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. , 1997, Circulation.
[46] B. Pitt,et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .
[47] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[48] J. Cleland,et al. Is the prognosis of heart failure improving? , 1999, Journal of the American College of Cardiology.
[49] M. Komajda,et al. Risk stratification in chronic heart failure. , 1998, European heart journal.
[50] E J Topol,et al. Cause of death in clinical research: time for a reassessment? , 1999, Journal of the American College of Cardiology.
[51] I. V. Van Gelder,et al. Heart failure and atrial fibrillation: current concepts and controversies. , 1997, Heart.
[52] T. Ogihara,et al. Reduction of risk of pneumonia associated with use of angiotensin I converting enzyme inhibitors in elderly inpatients. , 1999, American journal of hypertension.
[53] W. Remme. Prevention of worsening heart failure: future focus. , 1998, European heart journal.
[54] A. Hall,et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. , 1997, European heart journal.
[55] L. Køber,et al. Angiotensin-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study. , 1996, American heart journal.
[56] N. Bayley,et al. Failure , 1890, The Hospital.
[57] A. Hall,et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. , 1996, European heart journal.
[58] Dwight Lemon,et al. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1 , 1987 .